Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + docetaxel + doxorubicin + letrozole
- Development stage
- Preclinical
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination of three chemotherapeutic agents (cyclophosphamide, docetaxel, and doxorubicin) with an aromatase inhibitor (letrozole). The TAC/DAC component (docetaxel, doxorubicin, and cyclophosphamide) is a chemotherapy regimen used for breast cancer, while letrozole is an aromatase inhibitor that blocks estrogen production in postmenopausal women with hormone-sensitive breast cancer. Research has shown that letrozole can enhance the cytotoxic effects of doxorubicin and docetaxel in vitro, suggesting potential synergistic effects when combined.
- Other names
- TAC + letrozoleDAC + letrozole
02
Targets
TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))DNACYP19A1 (Aromatase)
Beyond the preview
Go deeper on cyclophosphamide + docetaxel + doxorubicin + letrozole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + docetaxel + doxorubicin + letrozole.